DelveInsight’s, “Acute Kidney Injury Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Acute Kidney Injury pipeline landscape. It covers the Acute Kidney Injury Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Kidney Injury Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Acute Kidney Injury Pipeline? @ https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight

Key Takeaways from the Acute Kidney Injury Pipeline Report

• On June 04, 2026- River 2 Renal Corp. initiated a Phase 2, dose-ranging, double-blind, double-dummy, placebo-controlled, randomized study preceded by an open label safety run-in, in patients at high risk for Cardiac Surgery Associated – Acute Kidney Injury (CSA-AKI) following coronary artery bypass graft (CABG), valve surgery, aortic surgery, or a combination of the above, involving cardiopulmonary bypass (CPB).
• On June 01, 2026- Novartis Pharmaceuticals conducted a phase 2b study is to characterize the dose-response relationship and to evaluate the safety and efficacy of three different single doses of TIN816 in hospitalized adult participants in an intensive care setting with a diagnosis of sepsis-associated acute kidney injury (SA-AKI).
• DelveInsight’s Acute Kidney Injury Pipeline report depicts a robust space with 20+ active players working to develop 25+ pipeline therapies for Acute Kidney Injury treatment.
• The leading Acute Kidney Injury Companies such as AstraZeneca, Arch Biopartners, Guard Therapeutics AB, M2RLAB SL, Keli Therapeutics, Curacle and others.
• Promising Acute Kidney Injury Therapies such as Conestat alfa (Ruconest®), Neseritide, GDC-8264, THR-184, ABT-719, QPI-1002, Ciclosporin and others.

Want to know which companies are leading innovation in Acute Kidney Injury? @ Acute Kidney Injury Clinical Trials Assessment

The Acute Kidney Injury Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Acute Kidney Injury Pipeline Report also highlights the unmet needs with respect to the Acute Kidney Injury.

Acute Kidney Injury Overview

Acute kidney injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it hard for kidneys to keep the right balance of fluid in body. AKI can also affect other organs such as the brain, heart, and lungs. Acute kidney injury is common in patients who are in the hospital, in intensive care units, and especially in older adults. There are rarely any symptoms until the condition has progressed to a late stage. However, if there are symptoms, the most common one is a decrease in urine output.

Acute Kidney Injury Emerging Drugs Profile

• Ravulizumab: AstraZeneca

Ravulizumab (Ultomiris) is a long-acting monoclonal antibody developed by AstraZeneca (Alexion) that inhibits complement protein C5, preventing downstream inflammatory damage. It is currently being evaluated in the Phase III ARTEMIS trial for the prevention of acute kidney injury (AKI) in patients with chronic kidney disease undergoing cardiac surgery. By blocking terminal complement activation, ravulizumab aims to reduce ischemia-reperfusion injury and lower the incidence of major adverse kidney events (MAKE) post-surgery. This represents a novel, targeted approach to address a major unmet need in perioperative renal protection. Currently, the drug is in the Phase III stage of its development for the treatment of Acute Kidney Injury.

• RMC-035: Guard Therapeutics AB

RMC-035, developed by Guard Therapeutics AB, is a first-in-class investigational biologic therapy based on a recombinant form of the endogenous protein alpha-1-microglobulin (A1M). It is designed to protect kidney cells from oxidative stress and damage, particularly during conditions such as open-heart surgery that can lead to acute kidney injury (AKI). The drug is administered via intravenous infusion as a short-term hospital treatment, aiming to reduce the risk of permanent kidney damage, dialysis, or death in high-risk patients. Currently, RMC-035 is in Phase 2b clinical development, following promising Phase II data showing improvements in long-term kidney function and reduction in major adverse kidney events. It has also received FDA Fast Track designation and IND clearance, highlighting its potential to address a significant unmet need in kidney protection. Currently the drug is in Phase II stage of its development.

• KELI-101: Keli Therapeutics

KELI-101, developed by Keli Therapeutics, is an investigational allogeneic placental mesenchymal stromal cell therapy designed to treat acute kidney injury (AKI). It is derived from a proprietary placental cell platform with strong immunomodulatory, anti-inflammatory, and regenerative properties, aiming to protect and repair kidney tissue. Preclinical studies have demonstrated that KELI-101 can improve survival, restore kidney function, and reduce inflammation and oxidative stress, supporting its therapeutic potential in AKI. Currently, the therapy is being evaluated in a Phase Ib/II clinical trial, particularly in patients at risk of kidney injury following cardiac surgery, reflecting its advancement into early clinical development.

If you’re tracking ongoing Acute Kidney Injury Clinical trials, this press release is a must-read @ Acute Kidney Injury Treatment Drugs

The Acute Kidney Injury Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
• Acute Kidney Injury Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.

Acute Kidney Injury Companies

AstraZeneca, Arch Biopartners, Guard Therapeutics AB, M2RLAB SL, Keli Therapeutics, Curacle and others.

Acute Kidney Injury Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Acute Kidney Injury Products have been categorized under various Molecule types such as,

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Acute Kidney Injury Pipeline Report @ Acute Kidney Injury Market Drivers and Barriers, and Future Perspectives

Scope of the Acute Kidney Injury Pipeline Report

• Coverage- Global
• Acute Kidney Injury Companies- AstraZeneca, Arch Biopartners, Guard Therapeutics AB, M2RLAB SL, Keli Therapeutics, Curacle and others.
• Acute Kidney Injury Therapies- Conestat alfa (Ruconest®), Neseritide, GDC-8264, THR-184, ABT-719, QPI-1002, Ciclosporin and others.
• Acute Kidney Injury Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Kidney Injury Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Acute Kidney Injury Treatment landscape in this detailed analysis @ Acute Kidney Injury Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Acute Kidney Injury: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Kidney Injury– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ravulizumab: AstraZeneca
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RMC-035: Guard Therapeutics AB
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. KELI-101: Kelifarma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Acute Kidney Injury Key Companies
21. Acute Kidney Injury Key Products
22. Acute Kidney Injury- Unmet Needs
23. Acute Kidney Injury- Market Drivers and Barriers
24. Acute Kidney Injury- Future Perspectives and Conclusion
25. Acute Kidney Injury Analyst Views
26. Acute Kidney Injury Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight